Detalles de la búsqueda
1.
Clinical characteristics of second primary cancer in colorectal cancer patients: the impact of colorectal cancer or other second cancer occurring first.
World J Surg Oncol
; 12: 73, 2014 Mar 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-24678904
2.
FOLFIRI combined with bevacizumab as first-line treatment for metastatic colorectal cancer patients with hyperbilirubinemia after UGT1A1 genotyping.
Med Princ Pract
; 23(5): 478-81, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-24642571
3.
High blood sugar levels but not diabetes mellitus significantly enhance oxaliplatin chemoresistance in patients with stage III colorectal cancer receiving adjuvant FOLFOX6 chemotherapy.
Ther Adv Med Oncol
; 11: 1758835919866964, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31467597
4.
High blood sugar levels significantly impact the prognosis of colorectal cancer patients through down-regulation of microRNA-16 by targeting Myb and VEGFR2.
Oncotarget
; 7(14): 18837-50, 2016 Apr 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-26934556
5.
Clinical Implication of UGT1A1 Promoter Polymorphism for Irinotecan Dose Escalation in Metastatic Colorectal Cancer Patients Treated with Bevacizumab Combined with FOLFIRI in the First-line Setting.
Transl Oncol
; 8(6): 474-9, 2015 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-26692528
6.
Prognostic advantage of irinotecan dose escalation according to uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) genotyping in patients with metastatic colorectal cancer treated with bevacizumab combined with 5-fluorouracil/leucovorin with irinotecan in a first-line setting.
Transl Res
; 164(2): 169-76, 2014 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-24462762
Resultados
1 -
6
de 6
1
Próxima >
>>